Top Markets
#1 Nesa Nesa +819.45%
#2 Cortex Cortex +68.87%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.70%
#4 QuantixAI QuantixAI +24.05%
#5 EXOD EXOD +22.78%
#6 OpenEden OpenEden +20.21%
#7 Palladium Network Palladium Network +18.98%
#8 Cash Cat Cash Cat +17.14%
#9 Instadapp Instadapp +16.92%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.48%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294
Rank in Stocks #3529
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Share Price
$4.64
Market Cap
$5.18B
Change (1 day)
0.41%
Change (1 year)
-37.42%
Country
CN
Trade Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Category

Healthcare
Operating Margin for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Operating Margin as of 2026 TTM: 0.00%
According to Shenzhen Salubris Pharmaceuticals Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Shenzhen Salubris Pharmaceuticals Co., Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
31.28% -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
12.36% -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
0.00% -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
9.83% -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.